Susquehanna International Group
AEON icon

Susquehanna International Group’s AEON Biopharma AEON Stock Holding History

Susquehanna International Group’s Portfolio AEON Stock Details AEON Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-859
Closed -$621K – 12468
2022
Q4 		$621K Buy
859
+150
+21% +$107K ﹤0.01% 7307
2022
Q3 		$503K Buy
+709
New +$502K ﹤0.01% 8469

Other funds holding AEON

SCM
Saba Capital Management New York $3.62B AUM 13% 1-Year Est. Return
GCL
Glazer Capital LLC New York $4.71B AUM 81.93% 1-Year Est. Return
FTCM
Fir Tree Capital Management New York $21.8M AUM 1.61% 1-Year Est. Return
ECP
Empyrean Capital Partners Los Angeles, California $3.07B AUM 34.24% 1-Year Est. Return
TCM
Tenor Capital Management New York $6.49B AUM 3.01% 1-Year Est. Return
PC
Periscope Capital Toronto, Ontario, Canada $902M AUM 6.51% 1-Year Est. Return
SIM
Sandia Investment Management Boston, Massachusetts $40.1M AUM 14.58% 1-Year Est. Return
CCA
Castle Creek Arbitrage Avon, Colorado $425M AUM 7.4% 1-Year Est. Return
SCM
Shaolin Capital Management Miami, Florida $2.71B AUM 64.83% 1-Year Est. Return
GCWM
Graham Capital Wealth Management Washington D.c., District of Columbia $113M AUM 11.26% 1-Year Est. Return

Susquehanna International Group's AEON Position: Q1 2023 in Review

Susquehanna International Group sold out of AEON Biopharma (AEON) in Q1 2023, closing a stake of 859 shares — an estimated $621K sold.

Susquehanna International Group first reported a position in AEON in Q3 2022 and held it in 2 quarters. The position peaked at $621K in Q4 2022. 21 funds tracked by Wall St. Rank hold AEON as of Q1 2023.

  • Susquehanna International Group reported no remaining AEON Biopharma position as of Q1 2023 after selling out during the quarter.
  • Susquehanna International Group sold 859 AEON Biopharma shares in Q1 2023, an estimated $621K.
  • Susquehanna International Group first reported a position in AEON Biopharma in Q3 2022 and held it in 2 quarters.
  • Susquehanna International Group's AEON Biopharma position peaked at $621K in Q4 2022.
  • 21 funds tracked by Wall St. Rank held AEON Biopharma as of Q1 2023.

Based on Susquehanna International Group's 13F filing for Q1 2023, filed 16 May 2023.